Nasdaq-listed Merus, an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates, has priced an underwritten public offering of 5,263,158 common shares at US$57.00 per share to raise US$300m….
The Netherlands: Merus raises US$300m from underwritten public offering
…
…






